# NEJM publishes Phase 1/2 GS030 results: 6 of 10 patients gain meaningful light sensitivity

Canonical page: https://technooptimist.io/stories/nejm-publishes-phase-1-2-gs030-results-6-of-10-patients-gain-meaningful-cc704123
Date: 8 Oct 2026
About: [GenSight Biologics](https://technooptimist.io/companies/gensight-biologics.md) · [GS030 optogenetic therapy](https://technooptimist.io/neurotech/gs030.md)
Original source: https://www.gensight-biologics.com/2026/10/08/gensight-biologics-and-the-15-20-national-hospital-announce-nejm-publication-on-gs030-phase-1-2-trial-results-in-late-stage-retinitis-pigmentosa/

The PIONEER trial of GS030 in late-stage retinitis pigmentosa was published in NEJM as "Optogenetic Therapy for Restoring Aspects of Visual Function". The trial was built to test safety; exploratory results showed measurable visual responses in some patients, and no systemic side effect was linked to the drug or injection.

## Key facts

- 6 of 10 participants had a clinically meaningful gain in light sensitivity
- 4 of 8 who did behavioural tests improved at detecting, locating or touching objects
- High-density EEG in a subset showed signals consistent with input reaching the visual cortex
- One severe ocular event resolved within minutes after eye drops

---

The Techno Optimist tracks every frontier of technology, program by program: https://technooptimist.io/ (a Markdown version of any page: add .md to its URL; site map for agents: https://technooptimist.io/llms.txt).
Data API (JSON, realtime stream): https://technooptimist.io/developers. People read 5 pages free, then Reader $10/month; these Markdown pages are open to agents.